|Group:||Group I (dsDNA)|
Orthopoxvirus is a genus of viruses in the family Poxviridae and subfamily Chordopoxvirinae. Vertebrates, including mammals and humans, and arthropods serve as natural hosts. There are currently ten species in this genus including the type species vaccinia virus. Diseases associated with this genus include smallpox, cowpox, horsepox, and monkeypox. The most famous member of the genus is variola virus, which causes smallpox. Variola was eradicated using vaccinia virus as a vaccine.
The Orthopoxviruses are enveloped with brick-shaped geometries and virion dimensions of about 200 nm wide and 250 nm long. Orthopoxvirus genomes are linear and around 170–250 kb in length.
|Genus||Structure||Symmetry||Capsid||Genomic Arrangement||Genomic Segmentation|
Viral replication is cytoplasmic. Entry into the host cell is achieved by attachment of the viral proteins to host glycosaminoglycans (GAGs), which mediates cellular endocytosis of the virus. Fusion of the viral envelope with the plasma membrane releases the viral core into the host cytoplasm. Expression of early-phase genes by viral RNA polymerase begins at 30 minutes post-infection. The viral core is completely uncoated as early expression ends, releasing the viral genome into the cytoplasm. At this point, intermediate genes are expressed, triggering genomic DNA replication by the viral DNA polymerase at approximately 100 minutes post-infection. Replication follows the DNA strand displacement model. Late genes are expressed from 140 min to 48 hours post-infection, producing all viral structural proteins. Assembly of progeny virions begins in cytoplasmic viral factories, producing an spherical immature particle. This virus particle matures into the brick-shaped intracellular mature virion (IMV). IMVs can be released upon cell lysis, or can acquire a second membrane from the Golgi apparatus and bud as extracellular enveloped virions (EEV). In this latter case, the virion is transported to the plasma membrane via microtubules.
|Genus||Host Details||Tissue Tropism||Entry Details||Release Details||Replication Site||Assembly Site||Transmission|
|Orthopoxvirus||Mammals; arthropods||None||Glycosaminoglycans||Lysis; budding||Cytoplasm||Cytoplasm||Respiratory; contact; zoonosis|
Some Orthopoxviruses, including monkeypox, cowpox and buffalopox viruses have the ability to infect non-reservoir species. Others, such as ectromelia and camelpox viruses, are highly host specific. Vaccinia virus, maintained in vaccine institutes and research laboratories, has a very wide host range. Vaccine-derived vaccinia has been found replicating in the wild in Brazil, where it has caused infections in rodents, cattle, and even humans. Following the eradication of variola virus, camelpox has become one of the most economically important Orthopoxvirus infections due to the dependence of many subsistence-level nomadic communities on camels.
Human Orthopoxvirus Disease
Following the eradication of the human-specific variola virus, all human Orthopoxvirus infections are zoonoses. Monkeypox occurs naturally only in Africa, particularly in the Democratic Republic of the Congo. However, human and prairie dog cases have occurred in the US due to contact with animals imported from Ghana. Cowpox only occurs in Europe and adjacent Russian states and, despite its name, occurs only rarely in cattle. One common host is the domestic cat, from which human infections are most often acquired. Cowpox virus has also infected a variety of animals in European zoos, such as elephants, resulting in human infection.
Aerosols of concentrated virus may result in Orthopoxvirus infection, especially in non-immunized individuals. In addition, needle sticks with concentrated virus or scratches from infected animals may result in local infection of the skin even in immunized individuals. Cowpox infection in Europe is an occupational hazard for veterinary workers, and, to a lesser extent, farm workers.
Signs and Symptoms
The initial symptoms of Orthopoxvirus infection include fever, malaise, head and body aches, and occasionally vomiting. With the exception of monkeypox infection, one lesion is the norm, although satellite lesions may be produced by accidental auto-inoculation. Individual lesions, surrounded by inflammatory tissue, develop and progress through macules, papules, vesicles, and pustules, and eventually become dry crusts. (It should be noted that lesions alone are not diagnostic for Orthopoxvirus infection and may be mistaken for zoonotic Parapoxvirus infections or anthrax or Herpesvirus infections.) Severe edema and erythema may affect large areas of the body in cases of severe infection. Encephalitis (alteration of mental status and focal neurologic deficits), myelitis (upper- and lower-motor neuron dysfunction, sensory level and bowel and bladder dysfunction), or both may result from Orthopoxvirus infection. Rarely, Orthopoxviruses may be detected in cerebrospinal fluid.
Regarding specific Orthopoxvirus infections, human monkeypox most resembles mild smallpox. Human cowpox is a relatively severe localized infection. A survey of 54 cases reported three cases of generalized infection, including one death.
Vaccinia-specific immunoglobulins may be administered to infected individuals. The only product currently available for treatment of complications of Orthopoxvirus infection is vaccinia immunoglobulin (VIG), which is an isotonic sterile solution of the immunoglobulin fraction of plasma from persons vaccinated with vaccinia virus. It is effective for treatment of eczema vaccinatum and certain cases of progressive vaccinia. However, VIG is contraindicated for the treatment of vaccinial keratitis. VIG is recommended for severe generalized vaccinia if the patient is extremely ill or has a serious underlying disease. VIG provides no benefit in the treatment of postvaccinal encephalitis and has no role in the treatment of smallpox. Current supplies of VIG are limited, and its use is reserved for treatment of vaccine complications with serious clinical manifestations. The recommended dosage of the currently available VIG is 0.6 ml/kg of body weight. VIG must be administered intramuscularly and is ideally administered as early as possible after the onset of symptoms. Because therapeutic doses of VIG might be substantial (e.g., 42 ml for a person weighing 70 kg), the product may be administered in divided doses over a 24- to 36-hour period. Doses can be repeated, usually at intervals of 2–3 days, until recovery begins (i.e., no new lesions appear). The CDC is currently the only source of VIG for civilians.
The Food and Drug Administration has not approved the use of any antiviral compound for the treatment of Orthopoxvirus infections, including vaccinia virus and smallpox. However, certain antiviral compounds such as tecovirimat (ST-246) have been reported to be 100% active against vaccinia virus or other Orthopoxviruses in vitro and among test animals. Tecovirimat has been granted orphan drug status by the FDA and is currently under study to determine its safety and effectiveness in humans.
Imatinib, a compound approved by the FDA for cancer treatment, has been shown to limit the release of extracellular enveloped virions and to protect mice from a lethal challenge with vaccinia. Currently, imatinib and related compounds are being evaluated by the CDC for their efficacy against variola virus and monkeypox virus.
- "Viral Zone". ExPASy. Retrieved 15 June 2015.
- ICTV. "Virus Taxonomy: 2014 Release". Retrieved 15 June 2015.
- Trindade, Giliane S.; Emerson, Ginny L.; Carroll, Darin S.; Kroon, Erna G.; Damon, Inger K. (2007-07-01). "Brazilian Vaccinia Viruses and Their Origins". Emerging Infectious Diseases 13 (7): 965–972. doi:10.3201/eid1307.061404. ISSN 1080-6040. PMC 2878226. PMID 18214166.
- Baxby, Derrick (1988). "Human poxvirus infection after the eradication of smallpox". Epidem, Inf. 100: 321–34.
- Jezek, Z.; Fenner, F. (1988). Human monkeypox. Basel: Karger. ISBN 3 8055 4818 4.
- "Update:Multistate Outbreak of Monkeypox - Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003". MMWR 52 (27): 642–6. 2003.
- Bennett, M; Gaskell, C.J.; Baxby, D.; Gaskell, R.M.; Kelly, D.F.; Naidoo, J. (1990). "Feline cowpox virus infection". J. Small Anim. Pract. 31: 167–73.
- Baxby, D.,; Bennett, M.; Getty, B. (1994). "Human cowpox 1969-93: a review based on 54 cases". Brit. J. Derm. 131: 598–607.
- Kurth, A.; Wibbelt G; Gerber H-P; Petschaelis A; Pauli G; Nitsche A. (April 2008). "Rat-to-Elephant-to-Human Transmission of Cowpox Virus". Emerg Infect 14 (4): 670–671. doi:10.3201/eid1404.070817. PMC 2570944. PMID 18394293.
- Martinez, Mark; Michael P. Bray; John W. Huggins. "A Mouse Model of Aerosol-Transmitted Orthopoxviral Disease". doi:10.1043/0003-9985(2000)124<0362:AMMOAT>2.0.CO;2. Retrieved 25 July 2012.
- Yang G, Pevear DC, Davies MH, et al. (Oct 2005). "An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge". J Virol. 79 (20): 13139–49. doi:10.1128/JVI.79.20.13139-13149.2005. PMC 1235851. PMID 16189015.
- Reeves, P. M.; Bommarius, B.; Lebeis, S.; McNulty, S.; Christensen, J.; Swimm, A.; Chahroudi, A.; Chavan, R.; Feinberg, M. B.; Veach, D.; Bornmann, W.; Sherman, M.; Kalman, D. (2005). "Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases". Nature Medicine 11 (7): 731–739. doi:10.1038/nm1265. PMID 15980865.